Virological failure, HIV-1 drug resistance, and early mortality in adults admitted to hospital in Malawi: an observational cohort study

[1]  Ravindra K. Gupta,et al.  Virological Failure, HIV-1 Drug Resistance and Early Mortality in Adults Admitted to Hospital in Malawi: A Nested Observational Cohort Study , 2020 .

[2]  P. Drain,et al.  Point-of-care HIV viral load testing combined with task shifting to improve treatment outcomes (STREAM): findings from an open-label, non-inferiority, randomised controlled trial. , 2020, The lancet. HIV.

[3]  Ingrid A. Beck,et al.  Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial. , 2019, The lancet. HIV.

[4]  R. Gupta,et al.  Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I , 2019, The Journal of infectious diseases.

[5]  F. Raffi,et al.  Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for virologically suppressed people living with chronic HIV infection: the randomized non-inferiority MONCAY trial. , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Gatell,et al.  Prevalence of Pretreatment and Acquired HIV-1 Mutations Associated with Resistance to Lamivudine or Rilpivirine: A Systematic Review , 2019, Antiviral therapy.

[7]  A. Vos,et al.  Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. , 2019, The New England journal of medicine.

[8]  M. Peeters,et al.  Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. , 2019, The New England journal of medicine.

[9]  R. Gupta,et al.  The Impact of HIV-1 Drug Escape on the Global Treatment Landscape. , 2019, Cell host & microbe.

[10]  D. Katzenstein,et al.  Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis , 2019, EClinicalMedicine.

[11]  C. Cohen,et al.  Differentiated HIV care in sub-Saharan Africa: a scoping review to inform antiretroviral therapy provision for stable HIV-infected individuals in Kenya , 2018, AIDS care.

[12]  S. Lawn,et al.  Rapid urine-based screening for tuberculosis in HIV-positive patients admitted to hospital in Africa (STAMP): a pragmatic, multicentre, parallel-group, double-blind, randomised controlled trial , 2018, The Lancet.

[13]  T. Le.  World Health Organization Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy , 2018 .

[14]  J. Ousley,et al.  High Proportions of Patients With Advanced HIV Are Antiretroviral Therapy Experienced: Hospitalization Outcomes From 2 Sub-Saharan African Sites , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  N. Ford,et al.  Managing Advanced HIV Disease in a Public Health Approach , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Tulio de Oliveira,et al.  HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis , 2017, The Lancet. Infectious diseases.

[17]  P. Easterbrook,et al.  Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial , 2017, The lancet. HIV.

[18]  W. El-Sadr,et al.  Clinical decision tools are needed to identify HIV-positive patients at high risk for poor outcomes after initiation of antiretroviral therapy , 2017, PLoS medicine.

[19]  Huldrych F. Günthard,et al.  Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration , 2017, EBioMedicine.

[20]  J. V. van Oosterhout,et al.  Challenges with targeted viral load testing for medical inpatients at Queen Elizabeth Central Hospital in Blantyre, Malawi. , 2017, Malawi medical journal : the journal of Medical Association of Malawi.

[21]  R. Shafer,et al.  Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study , 2016, The Lancet. Infectious diseases.

[22]  R. Walensky,et al.  Rapid urine-based screening for tuberculosis to reduce AIDS-related mortality in hospitalized patients in Africa (the STAMP trial): study protocol for a randomised controlled trial , 2016, BMC Infectious Diseases.

[23]  Huldrych F. Günthard,et al.  Global epidemiology of drug resistance after failure of WHO recommended fi rst-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study , 2019 .

[24]  S. Lawn,et al.  HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up , 2015, Medicine.

[25]  N. Ford,et al.  Causes of hospital admission among people living with HIV worldwide: a systematic review and meta-analysis. , 2015, The lancet. HIV.

[26]  J. Samuel,et al.  Prevalence of HIV and Disease Outcomes on the Medical and Surgical Wards at Kamuzu Central Hospital, Lilongwe, Malawi , 2013, Tropical medicine and health.

[27]  J. Nachega,et al.  Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. , 2013, The Journal of infectious diseases.

[28]  R. Shafer.  Rationale and uses of a public HIV drug-resistance database. , 2006, The Journal of infectious diseases.

[29]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[30]  K. Dooley,et al.  Dolutegravir-based Antiretroviral Therapy for Patients Coinfected With Tuberculosis and Human Immunodeficiency Virus: A Multicenter, Noncomparative, Open-label, Randomized Trial , 2019 .

[31]  Peter Piot,et al.  Joint United Nations Program on HIV/AIDS (UNAIDS) , 1997 .